This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Green, B. A.
Right arrow Articles by Zlotnick, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Green, B. A.
Right arrow Articles by Zlotnick, G. W.

 Previous Article  |  Next Article 

Infection and Immunity, July 2005, p. 4454-4457, Vol. 73, No. 7
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.7.4454-4457.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Certain Site-Directed, Nonenzymatically Active Mutants of the Haemophilus influenzae P4 Lipoprotein Are Able To Elicit Bactericidal Antibodies

Bruce A. Green,1* Elizabeth Baranyi,1 Thomas J. Reilly,2,{dagger} Arnold L. Smith,2,{ddagger} and Gary W. Zlotnick1

Wyeth Vaccines Discovery Research, 401 N. Middletown Rd., Pearl River, New York 10965,1 Department of Molecular Microbiology and Immunology, University of Missouri Medical School, Columbia, Missouri 652122

Received 15 December 2004/ Returned for modification 25 January 2005/ Accepted 21 February 2005

The Haemophilus influenzae P4 lipoprotein (hel) is a potential component of a nontypeable H. influenzae otitis media vaccine. Since P4 is known to be an enzyme, nonenzymatically active forms of recombinant P4 are required. After site-directed mutagenesis of the hel gene, three of the mutated proteins were shown to be vaccine candidates.

* Corresponding author. Mailing address: Vaccines Discovery Research, Bldg. 205/3104, Wyeth Vaccines, 401 N. Middletown Road, Pearl River, NY 10965. Phone: (845) 602-2754. Fax: (845) 602-5536. E-mail: greenba{at}wyeth.com.

Editor: J. N. Weiser

{dagger} Present address: Department of Pathobiology, College of Veterinary Medicine, University of Missouri, Columbia, MO 65212.

{ddagger} Present address: Seattle Biomedical Research Institute, 307 Westlake Avenue, Suite 500, Seattle, WA 98109.

Infection and Immunity, July 2005, p. 4454-4457, Vol. 73, No. 7
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.7.4454-4457.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Reilly, T. J., Chance, D. L., Calcutt, M. J., Tanner, J. J., Felts, R. L., Waller, S. C., Henzl, M. T., Mawhinney, T. P., Ganjam, I. K., Fales, W. H. (2009). Characterization of a Unique Class C Acid Phosphatase from Clostridium perfringens. Appl. Environ. Microbiol. 75: 3745-3754 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»